CTRI/2013/08/003882
Recruiting
Phase 3
Phase III Randomised controlled trial comparing D2 versus D3 lymphadenectomy on outcomes of non-metastatic, resectable, but locally advanced, gastric cancer following neoadjuvant (perioperative) chemotherapy (ELANCe trial) - ELANCe
ConditionsHealth Condition 1: null- Gastric Cancer
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- Gastric Cancer
- Sponsor
- Tata Memorial Hospital
- Enrollment
- 287
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •ECOG performance status of 0 â?? 1 in patients deemed fit to undergo surgery at the pre\-anaesthetic check
- •\-Histologically proven gastric adenocarcinoma
- •\-No evidence of distant metastases, or locally advanced inoperable disease, as evaluated by computed tomography, chest radiography, ultrasonography, and / or laparotomy
- •\-Patient able to provide valid informed consent
- •\-Patient completed at least 1 cycle of neoadjuvant chemotherapy
Exclusion Criteria
- •Presence of any 1 of the following:
- •\-Previous or concomitant other cancer
- •\-Primary Oesophageal involvement extending to the stomach
- •\-Distant hepatic / extrahepatic disease discovered on laparotomy
- •\-Gross local disease in the porta precluding a curative resection
- •\-Patient did not consent for the trial
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Comparison of paclitaxel, liposomal doxorubicin (and, i.a. carboplatin) with epirubicin, paclitaxel and cyclophosphamide for neoadjuvant treatment of high-risk early breast cancerEUCTR2014-000619-14-DEGerman Breast Group
Completed
Phase 3
Study to find out if restricting raw fruits in patients with blood cancer can reduce infections.Health Condition 1: C910- Acute lymphoblastic leukemia [ALL]Health Condition 2: C920- Acute myeloblastic leukemiaHealth Condition 3: null- Patients with acute lymphoblastic leukemia or acute myeloid leukemiaCTRI/2018/01/011418Cancer Institute200
Completed
Phase 3
Steroid tablets for preventing tiredness in cancer patients receiving chemotherapy medicine.Health Condition 1: C509- Malignant neoplasm of breast of unspecified siteHealth Condition 2: C348- Malignant neoplasm of overlappingsites of bronchus and lungCTRI/2018/08/015222Cancer Institute126
Not yet recruiting
Phase 2
Randomized phase II/III trial comparing dose-dense Paclitaxel and Carboplatin (TC) therapy and conventional triweekly TC therapy for newly diagnosed or recurrent uterine carcinosarcomaJPRN-UMIN000025884Japanese Gynecologic Oncology Group400
Active, not recruiting
Phase 3
Randomized controlled trial of Primary Debulking Surgery (PDS) and Neoadjuvant Chemotherapy + Interval Debulking Surgery (NAC / IDS) in patients with stage IIIC / IV ovarian cancerOvarian cancer, Fallopian tube cancer, primary peritoneal cancerOvary, fallopian tube, peritoneumJPRN-jRCTs051190090Kato Kazuyoshi488